Mira Kyivska

Will Injective extend losses amid weak momentum and seller control?

Will Injective extend losses amid weak momentum and seller control?
Injective slides 8.08% despite $1.5B milestone

Injective (INJ) is trading at $6.09, down 8.08% over the last 24 hours. The asset has moved lower on the day and is positioned below its short-term moving averages, while maintaining ground above longer-term levels.

INJ price prediction
24H -9.2%
$5.53
48H -11%
$5.42
7D -22.17%
$4.74
1M -11.66%
$5.38
3M -64.04%
$2.19
6M -77.18%
$1.39
12M 26.44%
$7.7
Current price: $6.09 -0.27 4.22%
Real-time Data 12:13
Daily range 5.85 Arrow from to Icon 6.39
Weekly range 5.99 Arrow from to Icon 7.74
Loading...

Highlights

  • Pentiv has processed over $1.5 billion in tokenized mortgage records on the Injective blockchain, showing significant institutional activity.
  • Pentiv executed a $100 million digital asset treasury strategy focused on INJ, reflecting direct institutional allocations.
  • INJ/USD trades with bearish momentum and high volatility, with a projected range of $5.05 to $6.48 for the next two days.

Institutional flows grow as blockchain adoption meets sustained selling

Pentiv, formerly known as Pineapple Financial, has surpassed $1.5 billion in tokenized mortgage records processed on the Injective blockchain, according to Cointrust. This large-scale transaction volume marks a notable institutional use case for Injective’s infrastructure, showing practical integration of blockchain into traditional financial instruments. Additionally, Pentiv has implemented a $100 million digital asset treasury strategy centered on INJ, underlining direct treasury allocation by an institutional player. These developments highlight increasing institutional engagement with Injective, though price action has remained under broader selling pressure.

Injective asset chart
Injective price dynamics. Source: TradingView.

Bearish momentum intensifies as upside capped by resistance cluster

INJ is trading below the H1 SMA-20 at $6.16 and H1 SMA-50 at $6.59, while holding above the D1 SMA-200 at $5.91. The H1 Ichimoku Kijun at $6.29 is acting as immediate resistance and may cap any upside attempts in the short term. Technical indicators are mostly negative, with MACD showing a strong sell signal and ADX pointing to continued bearish momentum. RSI and CCI are both neutral, while Stoch RSI is in the overbought region, suggesting risk of a near-term pullback rather than a sustained reversal. Bull/Bear Power at -0.02 indicates sellers retain a marginal advantage intraday, and the Awesome Oscillator provides a neutral reading, leaving directional clarity to the downside signals.

Sideways action expected as downside risk outweighs reversal odds

In the next one to two trading days, INJ is expected to stay volatile within a broad range of $5.05 to $6.48. The forecast leans heavily towards a lower probability for upside attempts and an elevated likelihood of further downside movement. The baseline scenario anticipates sideways action between key support and resistance. A bullish reversal would require a decisive break and hold above $6.29, while a drop beneath $5.05 would open the way for a deeper retreat towards lower support levels.

Viktoras Karapetjanc, expert at Traders Union, views the surge of institutional activity on Injective — particularly Pentiv’s $1.5 billion in tokenized mortgages and $100 million treasury strategy — as strong evidence of real-world blockchain adoption. He highlights that, despite short-term downside pressure and a technical backdrop dominated by negative signals, macro and fundamental factors remain constructive. Karapetjanc notes that INJ’s ability to hold above the D1 SMA-200 at $5.91 adds underlying support, even as immediate resistance at the H1 Ichimoku Kijun at $6.29 limits bullish momentum. The expert sees potential for a reversal if INJ sustains above intraday resistance levels. "Institutional demand continues to strengthen Injective’s long-term outlook, so I remain constructive on the bigger picture despite short-term volatility."

Earlier, analysts noted that Injective remained under persistent selling pressure despite increased institutional activity and notable ecosystem developments. The current article reinforces the negative technical outlook and highlights the importance of monitoring the $5.05 support for signs of further downside risk in the coming sessions.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.